RESUMEN
Atractylodin is a major compound in the rhizome of Atractylodes lancea, an oriental herbal medicine used for the treatment of gastrointestinal diseases, including dyspepsia, nausea, and diarrhea. Recent studies have shown that atractylodin exerts anti-inflammatory effects in various inflammatory diseases. Herein, we investigated the anti-colitis effects of atractylodin and its molecular targets. We determined the non-cytotoxic concentration of atractylodin (50 µM) using a cell proliferation assay in colonic epithelial cells. We found that pretreatment with atractylodin significantly inhibits tumor necrosis factor-α-induced phosphorylation of nuclear factor-κ-light-chain-enhancer of activated B in HCT116 cells. Through docking simulation analysis, luciferase assays, and in vitro binding assays, we found that atractylodin has an affinity for peroxisome proliferator-activated receptor alpha (PPARα). Daily administration of atractylodin (40 mg/kg) increased the survival rate of mice in a dextran sodium sulfate-induced colitis mouse model. Thus, atractylodin can be a good strategy for colitis therapy through inducing PPARα-dependent pathways.
Asunto(s)
Colitis , PPAR alfa , Animales , Ratones , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Fosforilación , Furanos/química , Ratones Endogámicos C57BL , Sulfato de DextranRESUMEN
Through activity-guided fractionation, a new triterpene (asperflagin, 1) was isolated as a PPAR-γ agonist from the jellyfish-derived fungus Aspergillus flavus. Asperflagin displayed selective and moderate transactivation effects on PPAR-γ in Ac2F rat liver cells. Based on further biological evaluation and molecular docking analysis, we postulated that asperflagin might function as a PPAR-γ partial agonist. This compound was calculated to display a typical PPAR-γ ligand-receptor interaction that is distinct from that of full agonistic antidiabetics such as rosiglitazone, and may retain the antidiabetic effect without accompanying weight gain. Weight gain and obesity are typical side effects of the PPAR-γ full agonist rosiglitazone, and lead to suboptimal outcomes in diabetic patients. Compared to rosiglitazone, asperflagin showed higher glucose uptake in HepG2 human liver cells at concentrations of 20 and 40 µM but induced markedly lower adipogenesis and lipid accumulation in 3T3-L1 preadipocytes. These results suggest that asperflagin may be utilized for further study on advanced antidiabetic leads.
Asunto(s)
Aspergillus flavus , Glucosa/metabolismo , PPAR gamma/agonistas , Triterpenos/farmacología , Adipogénesis/efectos de los fármacos , Animales , Línea Celular , Humanos , Metabolismo de los Lípidos/efectos de los fármacos , Ratones , Simulación del Acoplamiento Molecular , PPAR gamma/metabolismo , Ratas , Triterpenos/químicaRESUMEN
Peroxisome proliferator-activated receptor (PPAR) expression has been implicated in pathological states such as cancer, inflammation, diabetes, and neurodegeneration. We isolated natural PPAR agonists-eight 2,5-diketopiperazines-from the jellyfish-derived fungus Aspergillus flavus. Cyclo-(L-Pro-L-Phe) was the most potent PPAR-γ activator among the eight 2,5-DKPs identified. Cyclo-(L-Pro-L-Phe) activated PPAR-γ in Ac2F rat liver cells and SH-SY5Y human neuroblastoma cells. The neuroprotective effect of this partial PPAR-γ agonist was examined using the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, lactate dehydrogenase release, and the Hoechst 33342 staining assay in SH-SY5Y cells. Our findings revealed that cyclo-(L-Pro-L-Phe) reduced hydrogen peroxide-induced apoptosis as well as the generation of reactive oxygen species. Rhodamine 123 staining and western blotting revealed that cyclo-(L-Pro-L-Phe) prevented the loss of mitochondrial membrane potential and inhibited the activation of mitochondria-related apoptotic proteins, such as caspase 3 and poly (ADP-ribose) polymerase. Moreover, cyclo-(L-Pro-L-Phe) inhibited the activation and translocation of nuclear factor-kappa B. Thus, the partial PPAR-γ agonist cyclo-(L-Pro-L-Phe) demonstrated potential neuroprotective activity against oxidative stress-induced neurodegeneration in SH-SY5Y cells.
Asunto(s)
Aspergillus flavus/química , Dicetopiperazinas/farmacología , Fármacos Neuroprotectores/farmacología , Escifozoos/microbiología , Animales , Organismos Acuáticos , Línea Celular/efectos de los fármacos , Línea Celular Tumoral/efectos de los fármacos , Humanos , Neuroblastoma/metabolismo , RatasRESUMEN
In our previous study, a PPAR-γ agonist (+)-(R,E)-6a1 was elaborated as an anti-inflammatory lead. However, in silico analysis showed that (+)-(R,E)-6a1 lacks key hydrogen bonding with Tyr473 of PPAR-γ LBD (ligand binding domain). To facilitate additional hydrogen bonding with Tyr473, a more polar head group was introduced to the structure of (+)-(R,E)-6a1, and we also attempted to synthesize enzymatically stable derivatives. Of the synthetic derivatives, compound (+)-(R,E)-5f showed highest PPAR-γ transcriptional activity and reasonable metabolic stability. Compound (+)-(R,E)-5f suppressed the expression of pro-inflammatory mediators such as inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α). Reduction of nitric oxide (NO), and ROS was also observed. Compound (+)-(R,E)-5f was found to suppress the NF-κB pathway by inhibiting phosphorylation of IKK (IκB kinase), and this may lead to subsequent inhibition of IκBα (inhibitor of NF-κBα) phosphorylation and inhibition of NF-κB activation. These results indicate that (+)-(R,E)-5f exerts anti-inflammatory activity via NF-κB pathway inhibition, and may serve as a potential anti-inflammatory lead.
Asunto(s)
Antiinflamatorios/química , Antiinflamatorios/farmacología , FN-kappa B/metabolismo , PPAR gamma/agonistas , Transducción de Señal/efectos de los fármacos , Animales , Línea Celular , Diseño de Fármacos , Ratones , Modelos Moleculares , FN-kappa B/antagonistas & inhibidores , PPAR gamma/metabolismo , Células RAW 264.7 , RatasRESUMEN
Microtubules play a crucial role in mitosis and are attractive targets for cancer therapy. Recently, we isolated viriditoxin, a cytotoxic and antibacterial compound, from a marine fungus Paecilomyces variotii. Viriditoxin has been reported to inhibit the polymerization of bacterial FtsZ, a tubulin-like GTPase that plays an essential role in bacterial cell division. Given the close structural homology between FtsZ and tubulin, we investigated the potential antimitotic effects of viriditoxin on human cancer cells. Viriditoxin, like paclitaxel, enhanced tubulin polymerization and stabilized microtubule polymers, thereby perturbing mitosis in the SK-OV-3 cell line. However, the morphology of the stabilized microtubules was different from that induced by paclitaxel, indicating subtle differences in the mode of action of these compounds. Microtubule dynamics are also essential in cell movement, and viriditoxin repressed migration and colony formation ability of SK-OV-3 cells. Based on these results, we propose that viriditoxin interrupts microtubule dynamics, thus leading to antimitotic and antimetastatic activities.
Asunto(s)
Antimitóticos/farmacología , Movimiento Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Microtúbulos/efectos de los fármacos , Mitosis/efectos de los fármacos , Naftoles/farmacología , Neoplasias Ováricas/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Femenino , Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos , Humanos , Microtúbulos/metabolismo , Microtúbulos/patología , Invasividad Neoplásica , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patologíaRESUMEN
In our previous study, a synthetic compound, (+)-(R,E)-6a1, that incorporated the key structures of anti-inflammatory algal metabolites and the endogenous peroxisome proliferator-activated receptor γ (PPAR-γ) ligand 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2), exerted significant PPAR-γ transcriptional activity. Because PPAR-γ expressed in macrophages has been postulated as a negative regulator of inflammation, this study was designed to investigate the anti-inflammatory effect of the PPAR-γ agonist, (+)-(R,E)-6a1. Compound (+)-(R,E)-6a1 displayed in vitro anti-inflammatory activity in lipopolysaccharides (LPS)-stimulated murine RAW264.7 macrophages. Compound (+)-(R,E)-6a1 suppressed the expression of proinflammatory factors, such as nitric oxide (NO), inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), possibly by the inhibition of the nuclear factor-κB (NF-κB) pathway. In macrophages, (+)-(R,E)-6a1 suppressed LPS-induced phosphorylation of NF-κB, inhibitor of NF-κB α (IκBα), and IκB kinase (IKK). These results indicated that PPAR-γ agonist, (+)-(R,E)-6a1, exerts anti-inflammatory activity via inhibition of the NF-κB pathway.
Asunto(s)
Antiinflamatorios/farmacología , Macrófagos/efectos de los fármacos , FN-kappa B/agonistas , PPAR gamma/antagonistas & inhibidores , Prostaglandinas Sintéticas/farmacología , Animales , Ciclooxigenasa 2/genética , Regulación de la Expresión Génica/efectos de los fármacos , Inflamación/inducido químicamente , Interleucina-6/genética , Lipopolisacáridos , Ratones , Óxido Nítrico/genética , Óxido Nítrico Sintasa de Tipo II/genética , Células RAW 264.7 , Rhodophyta/química , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
Two new cystine knot peptides, asteropsins F (ASPF) and G (ASPG), were isolated from the marine sponge Asteropus sp. ASPF and ASPG are composed of 33 and 32 amino acids, respectively, and contain six cysteines which are involved in three disulfide bonds. They shared the characteristic features of the asteropsin family, such as, N-terminal pyroglutamate modification, incorporation of cis prolines, and the unique anionic profile, which distinguish them from other knottin families. Tertiary structures of the peptides were determined by high resolution NMR. ASPF and ASPG were found to be remarkably resistant not only to digestive enzymes (chymotrypsin, pepsin, elastase, and trypsin) but also to thermal degradation. In addition, these peptides were pharmacologically inert; non-hemolytic to human and fish red blood cells, non-stimulatory to murine macrophage cells, and nontoxic in vitro or in vivo. These observations support their stability and biocompatibility as suitable carrier scaffolds for the design of oral peptide drug.
Asunto(s)
Materiales Biocompatibles/química , Miniproteínas Nodales de Cistina/química , Péptidos/química , Poríferos/química , Secuencia de Aminoácidos , Animales , Materiales Biocompatibles/aislamiento & purificación , Materiales Biocompatibles/farmacología , Línea Celular , Miniproteínas Nodales de Cistina/farmacología , Eritrocitos/efectos de los fármacos , Peces , Humanos , Macrófagos/efectos de los fármacos , Espectroscopía de Resonancia Magnética , Ratones , Modelos Moleculares , Péptidos/genética , Estabilidad Proteica , Estructura Terciaria de Proteína , Alineación de Secuencia , TemperaturaRESUMEN
Four new cytochalasin derivatives (1-4), together with proxiphomin (5), were isolated from a jellyfish-derived fungus Phoma sp. The planar structures and relative stereochemistry were established by analysis of 1D and 2D NMR data. The absolute configuration was defined by the modified Mosher's method. The compounds showed moderate cytotoxicity against a small panel of human solid tumor cell lines (A549, KB, and HCT116).
Asunto(s)
Citocalasinas/aislamiento & purificación , Hongos/química , Escifozoos/microbiología , Animales , Citocalasinas/química , Estructura Molecular , EstereoisomerismoRESUMEN
A series of N-substituted phthalimide derivatives were synthesized based on a pharmacophore study of paecilocin A (a natural PPAR-γ agonist) and synthetic leads. The introduction of hydrophilic and hydrophobic groups to the phthalimide skeleton yielded compounds 3-14. Compound 7 showed significant PPAR-γ activation in a luciferase assay using rat liver Ac2F cells. Docking simulations showed that a free hydroxyl group on the phthalimide head and a suitable hydrophilic tail, including a phenyl linker, were beneficial for PPAR-γ activation. Compound 7 and rosiglitazone concentration-dependently activated PPAR-γ with EC50 values of 0.67 µM and 0.028 µM, respectively. These phthalimide derivatives could be further investigated as a new class of PPAR-γ ligands.
Asunto(s)
Benzofuranos/farmacología , Lactonas/farmacología , PPAR gamma/efectos de los fármacos , Ftalimidas/farmacología , Tiazolidinedionas/farmacología , Animales , Benzofuranos/química , Productos Biológicos/química , Productos Biológicos/farmacología , Línea Celular , Relación Dosis-Respuesta a Droga , Interacciones Hidrofóbicas e Hidrofílicas , Lactonas/química , Ligandos , Hígado/citología , Hígado/efectos de los fármacos , Simulación del Acoplamiento Molecular , PPAR gamma/metabolismo , Ftalimidas/síntesis química , Ftalimidas/química , Ratas , Rosiglitazona , Tiazolidinedionas/administración & dosificaciónRESUMEN
Investigation of the secondary metabolites of the ascidian Herdmania momus led to the isolation and characterization of four new nucleoside derivatives (1-4). Structural studies showed that these derivatives represent a series of rare methylsulfinyladenosine derivatives of interconvertible transesterification isomers and/or sulfinyl epimers. The antiviral activities of these rare nucleosides were evaluated against a series of human pathogenic viruses.
Asunto(s)
Adenosina/aislamiento & purificación , Antivirales/química , Antivirales/farmacología , Nucleósidos/aislamiento & purificación , Urocordados/química , Virus/efectos de los fármacos , Adenosina/química , Animales , Cromatografía Líquida de Alta Presión , Espectroscopía de Resonancia Magnética , Estructura Molecular , Nucleósidos/química , EstereoisomerismoRESUMEN
Four new cytochalasin derivatives (1-4), together with cytochalasin B (5), were isolated from the fungus Phoma sp. obtained from the giant jellyfish Nemopilema nomurai. The planar structure and relative stereochemistry were established by analysis of 1D and 2D NMR data. The absolute configuration was defined by the modified Mosher's method. The compounds showed significant cytotoxicity against a small panel of human solid tumor cell lines (A549, SK-OV-3, SK-MEL-2, XF 498, and HCT15) with IC(50) values in the range of 0.5-30 µM. The cytochalasin B (5) showed obvious cytotoxicity with IC(50) of 7.9 µM against HeLa human cervical carcinoma cells.
Asunto(s)
Ascomicetos/química , Citocalasinas/farmacología , Escifozoos/microbiología , Animales , Antineoplásicos/química , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Citocalasinas/química , Relación Dosis-Respuesta a Droga , Detección Precoz del Cáncer , Humanos , Concentración 50 Inhibidora , Estructura MolecularRESUMEN
On the basis of a marine fungal phthalide (paecilocin A) skeleton, we synthesized 20 analogs and evaluated them for peroxisome proliferator-activated receptor gamma (PPAR-γ) binding and activation. Among these analogs, 6 and 7 had significant PPAR-γ binding activity, and 7 showed further PPAR-γ activation in rat liver Ac2F cells. In docking simulation, 7 formed H bonds with key amino acid residues of the PPAR-γ binding domain, and the overall positioning was similar to rosiglitazone. This new phthalide derivative is considered an interesting new molecular class of PPAR-γ ligands.
Asunto(s)
Benzofuranos/síntesis química , Benzofuranos/farmacología , Diseño de Fármacos , PPAR gamma/agonistas , Animales , Benzofuranos/química , Unión Competitiva , Línea Celular , Hígado/química , Modelos Moleculares , Estructura Molecular , RatasRESUMEN
A new cyclic tetrapeptide (1), along with known congeners (2, 3), was isolated from the fungus Phoma sp. derived from the giant jellyfish Nemopilema nomurai. The absolute configuration of 1 was determined using the modified Mosher's method and Marfey's method. Compound 1 displayed a weak suppressive effect on the production of nitric oxide (NO) in murine macrophage cells (RAW264.7) without notable cytotoxicity.
Asunto(s)
Ascomicetos/química , Péptidos Cíclicos/aislamiento & purificación , Escifozoos/microbiología , Animales , Línea Celular , Ratones , Modelos Moleculares , Conformación Molecular , Péptidos Cíclicos/químicaRESUMEN
Four new polyketides (1-4) were isolated from the fungus Paecilomyces variotii, which was derived from the jellyfish Nemopilema nomurai. The planar structures and relative configurations of these polyketides were elucidated on the basis of spectroscopic analyses, including 2D NMR experiments. The compounds showed inhibitory activity against pathogenic bacteria including methicillin-resistant Staphylococcus aureus 3089 and multi-drug-resistant Vibrio parahemolyticus 7001 with MIC values in the range 5-40 µg/mL.
Asunto(s)
Antibacterianos/aislamiento & purificación , Benzofuranos/aislamiento & purificación , Indanos/aislamiento & purificación , Macrólidos/aislamiento & purificación , Paecilomyces/química , Escifozoos/microbiología , Animales , Antibacterianos/química , Antibacterianos/farmacología , Benzofuranos/química , Benzofuranos/farmacología , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Indanos/química , Indanos/farmacología , Macrólidos/química , Macrólidos/farmacología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Océanos y Mares , Vibrio parahaemolyticus/efectos de los fármacosRESUMEN
In a search for effective PPAR-γ agonists, 110 clinical drugs were screened via molecular docking, and 9 drugs, including parecoxib, were selected for subsequent biological evaluation. Molecular docking of parecoxib to the ligand-binding domain of PPAR-γ showed high binding affinity and relevant binding conformation compared with the PPAR-γ ligand/antidiabetic drug rosiglitazone. Per the docking result, parecoxib showed the best PPAR-γ transactivation in Ac2F rat liver cells. Further docking simulation and a luciferase assay suggested parecoxib would be a selective (and partial) PPAR-γ agonist. PPAR-γ activation by parecoxib induced adipocyte differentiation in 3T3-L1 murine preadipocytes. Parecoxib promoted adipogenesis in a dose-dependent manner and enhanced the expression of adipogenesis transcription factors PPAR-γ, C/EBPα, and C/EBPß. These data indicated that parecoxib might be utilized as a partial PPAR-γ agonist for drug repositioning study.